Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty

Piotr Biega

Status: Completed

Conditions: Metastases to Bone

Treatments: Drug: Tranexamic acid injection

Study type: Observational

Funder types: Other

Identifiers

NCT06244498

01

Details and patient eligibility

About

This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.

Full description

Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.

Enrollment: 110 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patological fracture
• Arthroplasty using a modular prosthesis.

Exclusion criteria

• threatened fracture
• intraoperative blood transfusion
• fracture fixation

Trial design

110 participants in 2 patient groups

TXA

Description:

Tranexamic acid was administered to the participants at a dose of 1.0 g during the induction of anaesthesia and immediately after the operation.

Treatment:

Drug: Tranexamic acid injection

Non-TXA

Description:

Tranexamic acid were not administred to the participants .